Skip to content
Pharma Observatory a Scientist.com platform

Organization (Academic)

University of Molise

ClinicalTrials.gov lists University of Molise as lead sponsor of 19 trials. It has 1 active development program and 2 approved assets.

IT Academic
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

6 0 2008 2026

Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.

2026 is partial: 1 registered with a 2026 start date. The dashed outline is the pace from the 1 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 1.2 trial starts a year over the five years to September, under the 5 a year the method needs. 1 trial is registered to start in 2027 or later.

This page covers University of Molise: 19 lead-sponsored trials and 1 legal-entity registration.

Get the University of Molise report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Disease areas (28)

Shown in this order: most trials first.

Disease areas
Disease area Trials
Chalazion 2
Cognitive Dysfunction 2
Diabetes Mellitus 2
Diabetic Retinopathy 2
Ventricular Dysfunction 2

Trials by start year as sponsor or collaborator (12)

Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 1 trial is registered to start in 2027 or later, and not listed here.

Show the table of trials by start year as sponsor or collaborator
Trials by start year as sponsor or collaborator
Year Trials started
2026 (partial year) 1
2024 2
2023 3
2021 2
2020 1
2019 6
2017 1
2015 1
2014 1
2011 1

Recruitment duration, a model prediction: none of the 19 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

Active development programs (1)

Active development programs
Drug Disease area Max phase Trials
Control (placebo) group Cognitive Dysfunction Not reported 2

Approved assets (2)

Shown in this order: max phase first.

Approved assets
Drug Trials
OZODROP 1
"Hydrocortisone" 1

Sponsor delivery record (1)

Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.

Sponsor delivery record
Enrollment Timeline
2 of 2 hit target (n=2) 1 of 4 on time (n=4)

Journals published in (71)

Shown in this order: most published in first.

Journals published in
Journal Publications
Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie 7
Investigative ophthalmology & visual science 5
The ocular surface 4
Clinical & experimental ophthalmology 3
International journal of molecular sciences 3

US granted patents (1)

Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.

US granted patents
US patents granted Granted in the last 5 years Most recent grant
1 0 2013-06-25

Latest dated events (23)

Shown in this order: newest first.

Latest dated events
Date Event Source
2027-01-01 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))
2026-06-01 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))
2024-01-07 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))
2024-01-01 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))
2023-12-01 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))

Biomarkers this organization publishes on (194)

Shown in this order: most publications first.

Biomarkers this organization publishes on
Biomarker Publications
CRP 10
TNF 9
IL6 8
IL1B 6
VEGFA 5

Not on this page

Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, organization relationships, clia clinical laboratory certificates, and biomarker capability evidence.